NAPP PHARMACEUTICAL GROUP LIMITED

Active
Company number 00884285Private limited companyIncorporated 1966

Key figures

£135,303,000
Net assets 2025

† NAPP PHARMACEUTICAL GROUP LIMITED filed these accounts on paper, so Companies House publishes them only as a scanned image. The figures for the years marked † were read automatically from the scan and kept only where the statements add up (for example net assets equal total equity), but a reading error is still possible — check the original accounts at Companies House.

Ratios

2025

Sector comparison

SIC 21200

Where the company stands among the 519 active companies whose first SIC code is 21200 (Manufacture of pharmaceutical preparations).

Turnover£23,754,000
Around the median · median £23,754,000 among 43 that publish turnover
Net assets£135,303,000
Higher than 96% · median £63,413
Total assets£136,402,000
Higher than 95% · median £301,298
Cash£211,000
Higher than 63% · median £77,420
Company age60.3 years
Older than 97% · median 8.2 years
Largest in this sector by net assets
  1. GLAXO OPERATIONS UK LIMITED£1.1bn
  2. JAZZ PHARMACEUTICALS OPERATIONS UK LIMITED£465.3m
  3. TEVA PHARMA HOLDINGS LIMITED£369.8m
  4. NAPP PHARMACEUTICAL HOLDINGS LIMITED£322.1m
  5. ACTAVIS HOLDINGS UK II LIMITED£278.8m
  6. CURIA GLOBAL HOLDINGS LIMITED£204.6m
  7. TEVA UK LIMITED£191.5m
  8. CATALENT CTS (EDINBURGH) LIMITED£162m
  9. NAPP PHARMACEUTICAL GROUP LIMITED£135.3m
  10. TEVA NI LIMITED£114.3m

Positions are approximate. Figures come from each company's latest accounts; money and employee figures are compared only with companies that filed accounts in pounds for a period ending in the last two and a half years and are not dormant, so those groups are smaller than 519. The line on each bar marks the median.

Summary: NAPP PHARMACEUTICAL GROUP LIMITED

What kind of company is it?

NAPP PHARMACEUTICAL GROUP LIMITED is a private limited company registered with Companies House under company number 00884285. It was incorporated on 27 Jul 1966. Its status is active. The registered office is in Cambridge (CB4). Its nature of business (SIC 2007) is manufacture of pharmaceutical preparations (21200), wholesale of pharmaceutical goods (46460).

How is the company doing financially?

The latest accounts in the database are for 2025 (period ending 31 Dec 2025); the company files full accounts. Turnover was £23,754,000. Profit for the year was £861,000. Net assets were £135,303,000. Cash at bank and in hand was £211,000. Total assets were £136,402,000 and total liabilities £1,099,000.

How does it compare with similar companies?

Compared with 519 active companies whose first SIC code is 21200: By turnover it is around the median of the 43 that publish turnover (£23,754,000). By net assets it ranks higher than 96% of them (median £63,413). By total assets it ranks higher than 95% of them (median £301,298). By cash it ranks higher than 63% of them (median £77,420). It is older than 97% of them (median age 8.2 years).

Does it supply the public sector?

The company is named as a supplier in 6 public contract award notices from 3 public sector buyers since 2019. Contracts awarded to it alone have a combined published value of £1.1m. Its most frequent buyer is Velindre NHS Trust, NHS Wales Shared Services Partnership - Procurement Services (on beha… (4 contracts). 1 of the awards is shared with other suppliers, typically framework agreements.

What do public registers and reports show?

In its latest payment practices report it took an average of 119 days to pay suppliers, and 88% of invoices were not paid within agreed terms.

Who runs and controls the company?

One person with significant control is registered.

When are its next filings due?

The next accounts are due by 30 Sep 2027. The next confirmation statement is due by 12 Jun 2027.

Filed accounts2025
2025 †
Turnover23,754,000
Profit for the year861,000
Cash at bank and in hand211,000
Total assets136,402,000
Total liabilities1,099,000
Net assets / total equity135,303,000

A dash (—) means no accounts were filed for that year or the item is not in the accounts; 0 is a zero stated in the accounts. Small companies usually file only a balance sheet, so the profit and loss account is often missing.

Public contracts

6 contracts

NAPP PHARMACEUTICAL GROUP LIMITED is named as a supplier in 6 public contract award notices from 3 public sector buyers since 2019. The 5 contracts awarded to it alone with a published value add up to £1.1m. 1 award is shared with other suppliers and not counted in that total.

Contracts per year
Main buyers3
Velindre NHS Trust, NHS Wales Shared Services Partnership - Procurement Services (on beha…
4 contracts · £950.6k
eTenderwales
1 contract · £155.8k
NHS England
1 contract
Contracts
  1. Proprietary Drugs‡eTenderwales · £155,800
  2. Proprietary Drugs‡Velindre NHS Trust, NHS Wales Shared Services Partnership - Procurement Services (on beha… · £476,934
  3. Biosimilars and Biologics‡Velindre NHS Trust, NHS Wales Shared Services Partnership - Procurement Services (on beha… · £12,348
  4. Trastuzumab‡Velindre NHS Trust, NHS Wales Shared Services Partnership - Procurement Services (on beha… · £2,434
  5. Generic Drugs - Topicals & Miscellaneous‡Velindre NHS Trust, NHS Wales Shared Services Partnership - Procurement Services (on beha… · £458,863
Show 1 more
  1. NHS Framework agreement for Branded Medicines - North of England - Tranche ANHS England · shared by 25 suppliers, up to £204,551,038 in total

From contract award notices on Contracts Finder (since 2016) and Find a Tender (since 2021), published by the Cabinet Office under the Open Government Licence v3.0. Values are as published by the buyer and usually cover the whole contract term; the total leaves out awards shared between several suppliers, where the published figure is a ceiling for all of them, placeholder values and single figures of £1 billion or more. Notices marked ‡ do not state a company number and were linked by an exact match on the registered name. Contracts below the publication thresholds and those of devolved buyers that publish elsewhere are not included.

Statutory reporting

Payment practices1 Jul 2024 – 31 Dec 2024
Average time taken to pay invoices
119 days
Invoices not paid within agreed terms
88%
Member of a payment code
No
  • Within 30 days 29%
  • 31 to 60 days 24%
  • After 60 days 47%
Earlier periods (6)
Period ending
Days to pay
Within 30 days
Late
30 Jun 2024
184
0%
75%
30 Jun 2023
18
100%
33%
31 Dec 2022
13
100%
0%
30 Jun 2022
17
75%
50%
31 Dec 2021
20
69%
38%
30 Jun 2021
25
69%
38%

View the latest report on GOV.UK

Figures the company reported itself to the government's Check payment practices service, Gender pay gap service and Modern slavery statement registry (Open Government Licence v3.0). Only large companies and employers with 250 or more staff have to report, so most companies have nothing here.

History

3 events
  1. Financial year 2025 endedAccounts: turnover £23.8m, net assets £135.3m
  2. Napp Pharmaceutical Holdings Limited registered as a person with significant control
  3. Company incorporatedPrivate limited company

Dates as recorded at Companies House: incorporation, name changes, officer appointments and resignations, current persons with significant control, and the end of each financial year with figures in the database. Former persons with significant control are not listed.